NYSE:PFE - Pfizer Stock Price, Price Target & More

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Pfizer announced a quarterly dividend on Thursday, April 26th. Investors of record on Friday, May 11th will be given a dividend of $0.34 per share on Friday, June 1st. This represents a $1.36 dividend on an annualized basis and a yield of 3.74%. The ex-dividend date is Thursday, May 10th. View Pfizer's Dividend History.

Pfizer declared that its board has initiated a share repurchase plan on Tuesday, December 19th 2017, which allows the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company's board believes its stock is undervalued.

Pfizer Inc. (NYSE:PFE) announced its earnings results on Tuesday, May, 1st. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.03. The biopharmaceutical company had revenue of $12.91 billion for the quarter, compared to analysts' expectations of $13.14 billion. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The firm's revenue for the quarter was up 1.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.69 EPS. View Pfizer's Earnings History.

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pfizer.

Pfizer issued an update on its FY18 earnings guidance on Tuesday, May, 1st. The company provided EPS guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.95. The company issued revenue guidance of $53.5-55.5 billion, compared to the consensus revenue estimate of $54.45 billion.

21 equities research analysts have issued 12-month price objectives for Pfizer's shares. Their predictions range from $36.00 to $45.00. On average, they expect Pfizer's stock price to reach $40.4167 in the next twelve months. View Analyst Ratings for Pfizer.

Pfizer saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 61,705,171 shares, an increase of 3.1% from the May 15th total of 63,688,761 shares. Based on an average daily volume of 19,319,820 shares, the short-interest ratio is currently 3.2 days. Approximately 1.1% of the company's shares are short sold. View Pfizer's Current Options Chain.

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), GlaxoSmithKline (GSK), Sanofi (SNY), Bayer (BAYRY), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Allergan (AGN), Celgene (CELG) and Shire (SHPG).

Headlines about PFE stock have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pfizer earned a coverage optimism score of 0.11 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 45.11 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Pfizer's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.72%), Northern Trust Corp (1.31%), Massachusetts Financial Services Co. MA (1.04%), Dimensional Fund Advisors LP (0.79%), Franklin Resources Inc. (0.75%) and Barrow Hanley Mewhinney & Strauss LLC (0.69%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

PFE stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Natixis, Swiss National Bank, FIL Ltd, Caisse DE Depot ET Placement DU Quebec, Levin Capital Strategies L.P., MUFG Securities EMEA plc and Legal & General Group Plc. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

PFE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, Robeco Institutional Asset Management B.V., Neuberger Berman Group LLC, Mackay Shields LLC, Teacher Retirement System of Texas, LSV Asset Management and Summit Trail Advisors LLC. View Insider Buying and Selling for Pfizer.

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PFE stock can currently be purchased for approximately $36.41.

Pfizer has a market capitalization of $217.04 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.